Which adverse effect is most commonly associated with the use of direct-acting antivirals (DAAs) for treating viral hepatitis in cancer patients?

Which adverse effect is most commonly associated with the use of direct-acting antivirals (DAAs) for treating viral hepatitis in cancer patients?

• A. Nausea
• B. Fatigue
• C. Rash
• D. Headache

Answer: (B)

Fatigue is frequently reported as an adverse effect associated with the use of direct-acting antivirals (DAAs) in treating viral hepatitis, especially in cancer patients. This population often has a heightened vulnerability to fatigue due to the underlying disease, the stress of cancer treatment, and potential nutritional deficits. DAAs work by targeting specific steps in the viral lifecycle, which can lead to improvements in liver function and a decrease in viral load, but as the body responds to the medication and the virus is suppressed, patients may experience energy depletion or general fatigue as a side effect. While nausea, rash, and headache can also occur with antiviral treatments, they are less commonly reported compared to fatigue. The specific biochemical processes and overall burden of treatment are likely contributors to the prevalent experience of fatigue, making it a significant aspect to address in the care of cancer patients undergoing treatment for viral hepatitis with DAAs.

Fatigue is frequently reported as an adverse effect associated with the use of direct-acting antivirals (DAAs) in treating viral hepatitis, especially in cancer patients. This population often has a heightened vulnerability to fatigue due to the underlying disease, the stress of cancer treatment, and potential nutritional deficits. DAAs work by targeting specific steps in the viral lifecycle, which can lead to improvements in liver function and a decrease in viral load, but as the body responds to the medication and the virus is suppressed, patients may experience energy depletion or general fatigue as a side effect.

While nausea, rash, and headache can also occur with antiviral treatments, they are less commonly reported compared to fatigue. The specific biochemical processes and overall burden of treatment are likely contributors to the prevalent experience of fatigue, making it a significant aspect to address in the care of cancer patients undergoing treatment for viral hepatitis with DAAs.